“Historic moment:” Today, the FDA gave Biogen’s investigational Alzheimer’s drug aducanumab its approval, with the requirement that they conduct a post-approval trial. In a…
In an unexpected twist, the advisory committee that convened today on the experimental Alzheimer’s treatment aducanumab overwhelmingly said that drugmaker Biogen has failed to…
Image: Phil Gutis receives an aducanumab infusion while carrying out his “silly shoe challenge.” Phil Gutis reflects on the significance of participating in the…
Biogen’s aducanumab — a human antibody-based drug that targets beta-amyloid plaques, which are found in the brains of people with Alzheimer’s — has gone…
“It’s Time for More Time” With the #MoreTime campaign, the Alzheimer’s Association has gone all in on aducanumab, the controversial new Alzheimer’s drug produced…
Biogen’s Alzheimer’s drug aducanumab encounters another bump in the road as the FDA delays its approval decision. The Federal Drug Administration has given itself…
If aducanumab — an experimental treatment that may slow the progression of Alzheimer’s — gets FDA approval, how will the healthcare system meet the anticipated…
In a surprising turn of events, the Advisory Committee of experts on Biogen’s experimental Alzheimer’s drug aducanumab recommended against FDA approval of the drug…
Today, the public gets a preview of FDA staff recommendations and drugmaker presentations in advance of this Friday’s advisory committee meeting to discuss Biogen’s…
In yet another encouraging step toward the development of what could be the first drug approved for Alzheimer’s disease, the Federal Drug Administration today…
In another step toward what could be the first treatment for early stage Alzheimer’s, Biogen and Eisai today said they have completed an application…
The U.S. Food and Drug Administration (FDA) has approved a re-dosing study for patients formerly enrolled in Biogen’s phase three clinical trials of its…
Last week, Biogen announced that its Alzheimer’s drug aducanumab was effective in combating Alzheimer’s disease after all, and that it would be reviving a…
Last week, Biogen announced that its Alzheimer’s drug aducanumab was effective in combating Alzheimer’s disease, and that it would be reviving a trial cancelled…
In a dizzying reversal, Biogen announced today that it would seek approval from the U.S. Food and Drug Administration (FDA) to begin marketing its…